drk1980 Forum Guru

Topics: 147 Posts: 1,038
| | 06/18/06 - 03:09 AM  
 
   
 
|   #1 |
Which antihypertensives are first line for blood pressure control in the face of diabetic nephropathy with azotemia? thanks
|
| dr in trouble Forum Guru

Topics: 62 Posts: 601
| | 06/18/06 - 09:09 AM  
 
   
 
|   #2 |
ACE inhibitors
___________________ If u want to do something, do it today as there is no tomorrow.
|
| drk1980 Forum Guru

Topics: 147 Posts: 1,038
| | 06/18/06 - 01:56 PM  
 
   
 
|   #3 |
thanks dr in tr..., but i was thinking, azotemia indicated toward development of renal insufficiency, thus would be a contraindication for ACE-I use. What would be the alternative to ACE-I in such a case? ARII-Blockers or..?
|
| AAAAA Forum Fanatic
Topics: 156 Posts: 1,991
| | 06/18/06 - 03:17 PM  
 
   
 
|   #4 |
First of all, ACEI is used in Type I diabetics for reduction of mortality. ARB is used for Type II Diabetics. The goal is 130/80.
___________________ seeking study partner in USMLE, Canadian MCC OSCE examination
|
| AAAAA Forum Fanatic
Topics: 156 Posts: 1,991
| | 06/18/06 - 03:23 PM  
 
   
 
|   #5 |
HCTZ is contradicated in azotemia patient. Azotemia: Azotemia may be precipitated or increased by the hydrochlorothiazide component of Micardis Plus (ARB). Cumulative effects of the drug may develop in patients with impaired renal function since the primary route of excretion is through the urine.
___________________ seeking study partner in USMLE, Canadian MCC OSCE examination
|
| AAAAA Forum Fanatic
Topics: 156 Posts: 1,991
| | 06/18/06 - 03:24 PM  
 
   
 
|   #6 |
CCB is the drug of choice. In Stage I, a process is damaging the kidneys but azotemia and clinical signs ... The usual antihypertensive medications are a calcium-channel blocker such
___________________ seeking study partner in USMLE, Canadian MCC OSCE examination
|
| jmn Forum Junior
Topics: 4 Posts: 31
| | 06/18/06 - 05:13 PM  
 
   
 
|   #7 |
is there a difference in Tx of HTN in DM I & DM II about ACEIs? Could u clear this doubt, dr AAAAA? Thx
|
|
| |
| | | | | | | |